Side Effects of Ozempic (Semaglutide) and Tirzepatide
Both Ozempic (semaglutide) and tirzepatide cause predominantly gastrointestinal side effects, with tirzepatide demonstrating a higher overall rate of GI adverse events but semaglutide showing greater risk for gallbladder disease.
Common Gastrointestinal Side Effects
Semaglutide (Ozempic)
The most frequently reported side effects include 1:
- Nausea (reported in 17-22% of patients) 2, 3
- Vomiting (6-10% of patients) 2, 3
- Diarrhea (12-16% of patients) 2, 3
- Abdominal pain 1
- Constipation 1
These GI symptoms are usually transient with longer-acting formulations and can be mitigated by gradual dose escalation 2, 4. The FDA label specifically notes these as the most common adverse reactions occurring in ≥5% of patients 1.
Tirzepatide
Tirzepatide shows a 2.94-fold increased risk of overall GI adverse events compared to placebo (95% CI: 2.61-3.32), which is notably higher than semaglutide's 1.68-fold increase 5. Specific rates include 3:
- Nausea (17-22% of patients)
- Diarrhea (13-16% of patients)
- Vomiting (6-10% of patients)
Most GI events with both medications are mild to moderate in severity and occur primarily during dose escalation 6, 3.
Serious Adverse Effects
Pancreatitis
Both medications carry warnings for acute pancreatitis 7, 8. The FDA label for Ozempic instructs patients to stop using the medication and seek immediate care if severe abdominal pain occurs that won't resolve 1. However, the LEADER trial with liraglutide (same drug class) did not demonstrate increased pancreatitis risk, and the FDA has not identified a definitive causal link 4.
Gallbladder Disease
Semaglutide demonstrates significantly elevated risk for gallbladder-related disorders, particularly cholelithiasis, with a 2.6-fold increased risk (95% CI: 1.40-4.82) 5. In contrast, tirzepatide showed no significant biliary risk in pooled analyses 5. Both GLP-1 receptor agonists as a class have been associated with increased risk of acute cholecystitis 6, 4.
Thyroid Concerns
Both medications are contraindicated in patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2) based on animal studies 9, 6.
Diabetic Retinopathy
Semaglutide was associated with increased diabetic retinopathy complications in the SUSTAIN-6 trial, hypothesized to relate to rapid blood glucose reduction 10, 4. Patients should undergo appropriate eye examinations before starting therapy if not completed within the last 12 months 4.
Hypoglycemia Risk
Both medications have minimal risk of hypoglycemia when used alone 7, 8. However, risk increases significantly when combined with 10, 1:
- Insulin (hypoglycemia risk increases substantially)
- Sulfonylureas (hypoglycemia risk increases by 50% with DPP-4 inhibitors as comparison) 8
Tirzepatide showed hypoglycemia rates of 0.2-1.7% depending on dose, while semaglutide showed 0.4% 3.
Renal Effects
Kidney problems including acute kidney injury can occur, particularly when GI side effects (diarrhea, nausea, vomiting) cause dehydration 1. The FDA label emphasizes drinking adequate fluids to reduce dehydration risk 1. Both medications should be used with caution in severe renal impairment or end-stage renal disease 10, 4.
Cardiovascular Effects
Both medications can cause modest elevations in heart rate 4. Blood pressure and heart rate should be monitored periodically 6, 10.
Gastric Emptying and Surgical Considerations
GLP-1 receptor agonists delay gastric emptying, which raises concerns about aspiration risk during anesthesia 2. This effect is more pronounced with short-acting formulations 4. Caution should be used in patients with prior gastric surgery, including bariatric surgery 10, 4.
Nutritional Deficiencies
Emerging evidence suggests GLP-1 receptor agonists may predispose users to micronutrient deficiencies through appetite suppression and altered absorption 11:
- Vitamin D deficiency (7.5% at 6 months, 13.6% at 12 months)
- Iron depletion (26-30% lower ferritin levels)
- Calcium and protein insufficiency contributing to lean mass loss
- Over 60% of users consumed below estimated requirements for calcium and iron 11
Comparative Safety Profile
Semaglutide showed a 38% higher risk of serious adverse events compared to placebo (95% CI: 1.10-1.73), with examples including abdominal pain, pancreatitis, cholelithiasis, cholecystitis, and suicidal ideation 6.
Tirzepatide demonstrates higher overall GI adverse event rates but potentially better tolerability in other domains, with some evidence suggesting less reported side effects overall and protective renal effects 12. Neither medication significantly increased hepatic or pancreatic adverse events in pooled analyses 5.
Clinical Monitoring Recommendations
Patients should be monitored for 2, 6:
- Gastrointestinal symptoms (especially during dose titration)
- Hypoglycemia (particularly if on insulin or sulfonylureas)
- Acute gallbladder disease
- Pancreatitis symptoms
- Suicidal ideation and behavior 9, 6
- Injection site reactions 9, 10
- Cardiac arrhythmia/tachycardia (consider beta blockers if symptomatic) 2